Royalty Pharma PLC Reports Director Changes and Compensation Updates
Ticker: RPRX · Form: 8-K · Filed: Apr 10, 2025 · CIK: 1802768
| Field | Detail |
|---|---|
| Company | Royalty Pharma PLC (RPRX) |
| Form Type | 8-K |
| Filed Date | Apr 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, director-change, executive-compensation
TL;DR
Royalty Pharma shuffled its board and updated exec pay. Keep an eye on governance.
AI Summary
Royalty Pharma plc announced on April 7, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the departure of a director and the election of a new director, alongside updates to compensatory arrangements for certain officers. These changes were filed with the SEC on April 10, 2025.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance matters such as director changes and compensation arrangements, which typically carry low inherent risk.
Key Numbers
- 001-39329 — SEC File Number (Identifies the company's filing history with the SEC.)
- 98-1535773 — I.R.S. Identification No. (Company's tax identification number.)
Key Players & Entities
- Royalty Pharma plc (company) — Registrant
- April 7, 2025 (date) — Earliest event reported
- April 10, 2025 (date) — Date of report
- 110 East 59th Street (location) — Principal executive offices address
- New York, New York 10022 (location) — Principal executive offices address
FAQ
Who departed from the board of directors?
The filing indicates the departure of a director, but the specific name is not provided in the provided text.
Who was elected to the board of directors?
The filing states the election of a director, but the specific name is not provided in the provided text.
What is the company's principal executive office address?
The company's principal executive offices are located at 110 East 59th Street, New York, New York 10022.
What is the SEC file number for Royalty Pharma plc?
The SEC file number for Royalty Pharma plc is 001-39329.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is April 7, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 10, 2025 regarding Royalty Pharma plc (RPRX).